Targeting Both Notch and ErbB-2 Signalling Pathways is Required for Prevention of ErbB-2-positive Breast Tumour Recurrence

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Aug 18

PMID 21847123

Citations 79

Authors

K Pandya

K Meeke

A G Clementz

A Rogowski

J Roberts

L Miele

K S Albain

C Osipo

Affiliations

Soon will be listed here.

Abstract

Background: We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both trastuzumab-sensitive and trastuzumab-resistant, ErbB-2-positive, BT474 breast tumours in vivo. We also studied if the combination therapy of lapatinib plus GSI can induce tumour regression of ErbB-2-positive breast cancer.

Methods: We generated orthotopic breast tumour xenografts from trastuzumab- or lapatinib-sensitive and trastuzumab-resistant BT474 cells. We investigated the antitumour activities of two distinct GSIs, LY 411 575 and MRK-003, in vivo.

Results: Our findings showed that combining trastuzumab plus a GSI completely prevented (MRK-003 GSI) or significantly reduced (LY 411 575 GSI) breast tumour recurrence post-trastuzumab treatment in sensitive tumours. Moreover, combining lapatinib plus MRK-003 GSI showed significant reduction of tumour growth. Furthermore, a GSI partially reversed trastuzumab resistance in resistant tumours.

Conclusion: Our data suggest that a combined inhibition of Notch and ErbB-2 signalling pathways could decrease recurrence rates for ErbB-2-positive breast tumours and may be beneficial in the treatment of recurrent trastuzumab-resistant disease.

Citing Articles

Identification of a Notch transcriptomic signature for breast cancer.

Braune E, Geist F, Tang X, Kalari K, Boughey J, Wang L Breast Cancer Res. 2024; 26(1):4.

PMID: 38172915 PMC: 10765899. DOI: 10.1186/s13058-023-01757-7.

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.

Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B MedComm (2020). 2023; 4(6):e427.

PMID: 38045829 PMC: 10693315. DOI: 10.1002/mco2.427.

The covert symphony: cellular and molecular accomplices in breast cancer metastasis.

Si H, Esquivel M, Mendoza Mendoza E, Roarty K Front Cell Dev Biol. 2023; 11:1221784.

PMID: 37440925 PMC: 10333702. DOI: 10.3389/fcell.2023.1221784.

Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia.

Lee C, Kim M, Park C, Jo W, Seo J, Kim S Nat Commun. 2023; 14(1):439.

PMID: 36707514 PMC: 9883495. DOI: 10.1038/s41467-023-36179-8.

EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling.

Wang Y, Chen P, Zhao M, Cao H, Zhao Y, Ji M Cell Death Dis. 2022; 13(10):910.

PMID: 36309484 PMC: 9617940. DOI: 10.1038/s41419-022-05354-y.

References

Slamon D, Pegram M . Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001; 28(1 Suppl 3):13-9. DOI: 10.1016/s0093-7754(01)90188-5. View

Sliwkowski M, Lofgren J, Lewis G, Hotaling T, Fendly B, Fox J . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26(4 Suppl 12):60-70. View

Osipo C, Gajdos C, Cheng D, Jordan V . Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol. 2005; 93(2-5):249-56. DOI: 10.1016/j.jsbmb.2004.12.005. View

Benz C, Scott G, Sarup J, Johnson R, Tripathy D, Coronado E . Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993; 24(2):85-95. DOI: 10.1007/BF01961241. View

Callahan R, Raafat A . Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2001; 6(1):23-36. DOI: 10.1023/a:1009512414430. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Kopan R, Ilagan M . The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-33. PMC: 2827930. DOI: 10.1016/j.cell.2009.03.045. View

Efferson C, Winkelmann C, Ware C, Sullivan T, Giampaoli S, Tammam J . Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010; 70(6):2476-84. DOI: 10.1158/0008-5472.CAN-09-3114. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

10.

Nahta R, Esteva F . Herceptin: mechanisms of action and resistance. Cancer Lett. 2006; 232(2):123-38. DOI: 10.1016/j.canlet.2005.01.041. View

11.

Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMC: 49066. DOI: 10.1073/pnas.89.10.4285. View

12.

ORegan R, Cisneros A, England G, Macgregor J, Muenzner H, Assikis V . Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst. 1998; 90(20):1552-8. DOI: 10.1093/jnci/90.20.1552. View

13.

Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M . HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?. Anticancer Agents Med Chem. 2008; 8(5):488-96. DOI: 10.2174/187152008784533062. View

14.

Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B . Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010; 16(12):3141-52. PMC: 3008160. DOI: 10.1158/1078-0432.CCR-09-2823. View

15.

Osipo C, Gajdos C, Liu H, Chen B, Jordan V . Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003; 95(21):1597-608. DOI: 10.1093/jnci/djg079. View

16.

Menendez J, Mehmi I, Lupu R . Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006; 24(23):3735-46. DOI: 10.1200/JCO.2005.04.3489. View

17.

Yan M, Callahan C, Beyer J, Allamneni K, Zhang G, Ridgway J . Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010; 463(7282):E6-7. DOI: 10.1038/nature08751. View

18.

Dievart A, Beaulieu N, Jolicoeur P . Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999; 18(44):5973-81. DOI: 10.1038/sj.onc.1202991. View

19.

Politi K, Feirt N, Kitajewski J . Notch in mammary gland development and breast cancer. Semin Cancer Biol. 2004; 14(5):341-7. DOI: 10.1016/j.semcancer.2004.04.013. View

20.

Bettenhausen B, Hrabe de Angelis M, Simon D, Guenet J, Gossler A . Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. Development. 1995; 121(8):2407-18. DOI: 10.1242/dev.121.8.2407. View